Loading...
Loading...
CTIC| Name | Value |
|---|---|
| Revenues | 18.2M |
| Cost of Revenue | 1.2M |
| Gross Profit | 17.1M |
| Operating Expense | 29.3M |
| Operating I/L | -12.2M |
| Other Income/Expense | -3.5M |
| Interest Income | 0.4M |
| Pretax | -15.7M |
| Income Tax Expense | -0.1M |
| Net Income/Loss | -15.6M |
CTI BioPharma Corp. is a biopharmaceutical company specializing in the acquisition, development, and commercialization of targeted therapies for blood-related cancers. Its flagship product, VONJO (pacritinib), is an investigational oral kinase inhibitor designed for the treatment of adult patients with myelofibrosis. The company generates revenue through the licensing and collaboration agreements with Teva Pharmaceutical Industries Ltd., S*BIO Pte Ltd., and Baxalta. With a focus on novel therapies and strategic partnerships, CTI BioPharma Corp. aims to address unmet medical needs in the field of blood-related cancers.
